This paper reports the preliminary results of a cohort study of 4544 British women receiving hormone replacement therapy (HRT). These women were recruited at 21 specialist menopause clinics around Britain. Up to the end of June 1983, the mean duration of HRT use per woman was 67 months of which, on average, 43% was‘opposed’use. In general, however, both the amount of progestogen given and the number of days per cycle for which it was given was less than would have been the case if the women had been receiving modern opposed therapy. The major focus of the study was to monitor mortality and cancer incidence in the cohort. The mortality results were broadly reassuring: overall mortality was significantly lower than expected on the basis of na...
BACKGROUND: Although breast cancer risk is greater in users of estrogen-progestin than estrogen-only...
Objective: To comparatively review available evidence on hormone replacement therapy (HRT) and cance...
Background: Although breast cancer risk is greater in users of estrogen-progestin than estrogen-only...
This paper reports the preliminary results of a cohort study of 4544 British women receiving hormone...
Objective.–To reexamine the mortality experience of a cohort of long-term users of hormone replaceme...
Background Hormone replacement therapy (HRT) is widely used and has proven benefits for women with m...
Funding This work was supported by Cancer Research UK (reference C37316/A29656). The funder had no r...
BACKGROUND: Current use of hormone-replacement therapy (HRT) increases the incidence of breast cance...
Introduction Hormone replacement therapy (HRT) can help women experiencing menopausal symptoms, but ...
AIM: The goal of this study was to evaluate the incidence of myocardial infarction, cancer and death...
Background. The Collaborative Group on Hormonal Factors in Breast Cancer has brought together and re...
The overall tumour incidence and breast cancer incidence related to hormone replacement therapy (HRT...
Background Current use of hormone-replacement therapy (HRT) increases the incidence of breast cancer...
BACKGROUND: Ovarian cancer is the fourth most common cancer in women in the UK, with about 6700 deve...
Many studies have analysed the relation between hormone replacement therapy use and breast cancer ri...
BACKGROUND: Although breast cancer risk is greater in users of estrogen-progestin than estrogen-only...
Objective: To comparatively review available evidence on hormone replacement therapy (HRT) and cance...
Background: Although breast cancer risk is greater in users of estrogen-progestin than estrogen-only...
This paper reports the preliminary results of a cohort study of 4544 British women receiving hormone...
Objective.–To reexamine the mortality experience of a cohort of long-term users of hormone replaceme...
Background Hormone replacement therapy (HRT) is widely used and has proven benefits for women with m...
Funding This work was supported by Cancer Research UK (reference C37316/A29656). The funder had no r...
BACKGROUND: Current use of hormone-replacement therapy (HRT) increases the incidence of breast cance...
Introduction Hormone replacement therapy (HRT) can help women experiencing menopausal symptoms, but ...
AIM: The goal of this study was to evaluate the incidence of myocardial infarction, cancer and death...
Background. The Collaborative Group on Hormonal Factors in Breast Cancer has brought together and re...
The overall tumour incidence and breast cancer incidence related to hormone replacement therapy (HRT...
Background Current use of hormone-replacement therapy (HRT) increases the incidence of breast cancer...
BACKGROUND: Ovarian cancer is the fourth most common cancer in women in the UK, with about 6700 deve...
Many studies have analysed the relation between hormone replacement therapy use and breast cancer ri...
BACKGROUND: Although breast cancer risk is greater in users of estrogen-progestin than estrogen-only...
Objective: To comparatively review available evidence on hormone replacement therapy (HRT) and cance...
Background: Although breast cancer risk is greater in users of estrogen-progestin than estrogen-only...